{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:29Z","timestamp":1740144029267,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40257-020-00506-2","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T11:02:41Z","timestamp":1580900561000},"page":"313-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?"],"prefix":"10.1007","volume":"21","author":[{"given":"Lauren B.","family":"Banks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"issue":"7","key":"506_CR1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"B Freeman","year":"2000","unstructured":"Freeman B, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med."},{"key":"506_CR2","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293\u20137.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"506_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134\u201344.","journal-title":"N Engl J Med."},{"issue":"10","key":"506_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"S Topalian","year":"2014","unstructured":"Topalian S, Sznol M, McDermott D, Kluger H, Carvajal R, Sharfman W, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020\u201331.","journal-title":"J Clin Oncol."},{"key":"506_CR5","doi-asserted-by":"crossref","unstructured":"Spigel D, McLeod M, Hussein MA, Waterhouse DM, Einhorn L, Horn L, et al. Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) (abstract no. 1297O). ESMO 2017 congress, 8\u201312 Sep 2017, Madrid.","DOI":"10.1093\/annonc\/mdx380.002"},{"issue":"10","key":"506_CR6","doi-asserted-by":"publisher","first-page":"6134","DOI":"10.1073\/pnas.77.10.6134","volume":"77","author":"JW Mier","year":"1980","unstructured":"Mier JW, Gallo RC. Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Nat Acad Sci USA. 1980;77(10):6134\u20138.","journal-title":"Proc Nat Acad Sci USA."},{"key":"506_CR7","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.1990.8.10.1650","volume":"8","author":"D Parkinson","year":"1990","unstructured":"Parkinson D, Abrams J, Wiernik P, Rayner A, Margolin K, Van Echo D, et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol. 1990;8:1650\u20136.","journal-title":"J Clin Oncol."},{"issue":"12","key":"506_CR8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","volume":"271","author":"S Rosenberg","year":"1994","unstructured":"Rosenberg S, Yang K, Topalian S, Schwartzentruber D, Weber J, Parkinson D, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271(12):907\u201313.","journal-title":"JAMA."},{"issue":"7","key":"506_CR9","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105\u201316.","journal-title":"J Clin Oncol."},{"issue":"1","key":"506_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-017-0307-5","volume":"5","author":"B Curti","year":"2017","unstructured":"Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, et al. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry. J Immunother Cancer. 2017;5(1):102.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"506_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/CJI.0b013e3182372636","volume":"35","author":"RW Joseph","year":"2012","unstructured":"Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother. 2012;35(1):66\u201372.","journal-title":"J Immunother."},{"issue":"8","key":"506_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med."},{"issue":"11","key":"506_CR13","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/annonc\/mdu441","volume":"25","author":"C Lebb\u00e9","year":"2014","unstructured":"Lebb\u00e9 C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, et al. Survival follow-up and\u00a0ipilimumab\u00a0retreatment of patients with advanced melanoma who received\u00a0ipilimumab\u00a0in prior phase II studies. Ann Oncol. 2014;25(11):2277\u201384.","journal-title":"Ann Oncol."},{"issue":"17","key":"506_CR14","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889\u201394.","journal-title":"J Clin Oncol."},{"issue":"16","key":"506_CR15","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and\u00a0ipilimumab\u00a0in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med."},{"key":"506_CR16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318.","journal-title":"Lancet Oncol."},{"key":"506_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"J Weber","year":"2015","unstructured":"Weber J, D\u2019Angelo S, Minor D, Hodi F, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial. Lanced Oncol. 2015;16:375\u201384.","journal-title":"Lanced Oncol."},{"issue":"4","key":"506_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med."},{"issue":"26","key":"506_CR19","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long G, Arance A, Grob J, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med."},{"issue":"1","key":"506_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey L, Lao C, et al. Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med."},{"issue":"4","key":"506_CR21","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138.","journal-title":"Ann Oncol."},{"issue":"9","key":"506_CR22","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, Arance A, Grob J, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label multicenter, randomized, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239\u201351.","journal-title":"Lancet Oncol."},{"key":"506_CR23","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"F Hodi","year":"2018","unstructured":"Hodi F, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Cowey C, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomized, phase 3 trial. Lancet Oncol. 2018;19:1480\u201392.","journal-title":"Lancet Oncol."},{"issue":"7","key":"506_CR24","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","volume":"30","author":"Y Jansen","year":"2019","unstructured":"Jansen Y, Rozeman E, Mason R, Goldinger S, Foppen M, Hoejberg L, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity; clinical outcomes in advanced melanoma. Ann Oncol. 2019;30(7):1154\u201361.","journal-title":"Ann Oncol."},{"key":"506_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000493193","volume":"96","author":"S Iivanainen","year":"2019","unstructured":"Iivanainen S, Koivunen J. Early PD-1 therapy discontinuation in responding metastatic cancer patients. Oncology. 2019;96:125\u201331.","journal-title":"Oncology."},{"key":"506_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.1999.17.1.304","volume":"17","author":"G Palmieri","year":"1999","unstructured":"Palmieri G, Strazzullo M, Ascierto P, Satriano S, Daponte A, Castello G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. J Clin Oncol. 1999;17:304\u201311.","journal-title":"J Clin Oncol."},{"issue":"2","key":"506_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/SLA.0b013e3182380f56","volume":"255","author":"S Hoshimoto","year":"2012","unstructured":"Hoshimoto S, Faries M, Morton D, Shingai T, Kuo C, Wang H, et al. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg. 2012;255(2):357\u201362.","journal-title":"Ann Surg."},{"issue":"10","key":"506_CR28","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1073\/pnas.1719264115","volume":"115","author":"X Hong","year":"2018","unstructured":"Hong X, Sullivan R, Kalinich M, Kwan T, Giobbie-Hurder A, Pan S, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci USA. 2018;115(10):2467\u201372.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"225","key":"506_CR29","first-page":"1","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Argawal N, et al. Detection of circulating tumor DNA in early and late-stage human malignancies. Sci Transl Med. 2014;6(225):1\u201311.","journal-title":"Sci Transl Med."},{"issue":"39","key":"506_CR30","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"E Gray","year":"2015","unstructured":"Gray E, Rizos H, Reid A, Boyd S, Pereira M, Lo K, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008\u201317.","journal-title":"Oncotarget."},{"key":"506_CR31","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"J Lee","year":"2017","unstructured":"Lee J, Long G, Boyd S, Menzies A, Tembe V, Guminski A, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28:1130\u20136.","journal-title":"Ann Oncol."},{"issue":"5","key":"506_CR32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","volume":"4","author":"J Lee","year":"2018","unstructured":"Lee J, Long G, Menzies A, Lo S, Guminski A, Whitbourne K, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma with anti-programmed cell death antibodies. JAMA Oncol. 2018;4(5):717\u201321.","journal-title":"JAMA Oncol."},{"key":"506_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/CMR.0000000000000355","volume":"27","author":"P Diamantopoulos","year":"2017","unstructured":"Diamantopoulos P, Gaggadi M, Kassi E, Benopoulou O, Anastasopoulou A, Gogas H. Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events. Melanoma Res. 2017;27:391\u20135.","journal-title":"Melanoma Res."},{"issue":"9","key":"506_CR34","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","volume":"58","author":"S Cho","year":"2017","unstructured":"Cho S, Lipson E, Im HJ, Rowe S, Gonzalez E, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET\/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58(9):1421\u20138.","journal-title":"J Nucl Med."},{"issue":"29","key":"506_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000016417","volume":"98","author":"K Amrane","year":"2019","unstructured":"Amrane K, Le Goupil D, Quere G, Delcroix O, Gouva S, Schick U, et al. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET\/CT in patients with melanoma. Medicine (Baltimore). 2019;98(29):1\u201312.","journal-title":"Medicine (Baltimore)."},{"key":"506_CR36","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","volume":"29","author":"A Tan","year":"2018","unstructured":"Tan A, Emmet L, Lo S, Liu V, Kapoor R, Carlino M, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol. 2018;29:2115\u201320.","journal-title":"Ann Oncol."},{"key":"506_CR37","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","volume":"46","author":"R Seban","year":"2019","unstructured":"Seban R, Nemer J, Marabelle A, Yeh R, Deutsch E, Ammari S, et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46:2298\u2013310.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"506_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2967\/jnumed.118.213652","volume":"60","author":"K Ito","year":"2019","unstructured":"Ito K, Teng R, Schoder H, Humm J, Ni A, Michaud L, et al. 18F-FDG-PET\/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. J Nucl Med. 2019;60(3):335\u201341.","journal-title":"J Nucl Med."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00506-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-020-00506-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00506-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:56:31Z","timestamp":1612400191000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-020-00506-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00506-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"type":"print","value":"1175-0561"},{"type":"electronic","value":"1179-1888"}],"subject":[],"published":{"date-parts":[[2020,2,5]]},"assertion":[{"value":"5 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Lauren B. Banks declares that she has no conflicts of interest that might be relevant to the contents of this manuscript. Ryan J. Sullivan reports receiving research support from Merck and Amgen, has served as an independent monitor of a trial funded by Boehringer Ingelheim, and has served as a consultant for Array BioPharma, Amgen, Asana Biosciences, Bristol Myers Squibb, Novartis, Genentech, Replimune, and Compugen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No external funding was used in the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}